Valvular Heart Disease Treatment Market

The valvular heart disease treatment market is estimated to observe expansive growth across the assessment period of 2019-2027 on the back of the rising incidence of cardiovascular diseases among a large chunk of the global populace.

• The lifestyle of many individuals around the globe has been affected due to hectic routines and changing food habits has resulted in an increase in the cardiovascular diseases and disorders.  All these factors will have a positive impact on the growth of the valvular heart disease treatment market.
• The expanding geriatric population numbers will serve as a vital growth-contributing factor for the valvular heart disease treatment market. The World Health Organization (WHO) has predicted that the global above 60 population number will nearly double from 12 percent to 22 percent between 2015 and 2050. These statistics highlight the need for valvular heart disease treatment in the near future. These aspects bode well for the growth of the valvular heart disease treatment market.
• Research and development activities play a major role in the growth of the valvular heart disease treatment market. The players focus on these activities for discovering insights. The insights help in increasing the customer base of the players in the valvular heart disease treatment market, ultimately contributing to the growth.  

Valvular Heart Disease Treatment Market

Valvular heart disease is any disease including any at least one than one of the four valves of the heart. The condition, for countless cases happens because of advanced age which isn't preventable. In addition, if not treated suitably on schedule, there are high dangers for valvular heart diseases to result in death owing to the seriousness of the case. As a matter of fact, valvular heart disease treatment market enjoys an upper hand over other cardiovascular disease treatment markets. Additionally, expanding number of coronary conduit diseases, appropriation of negligibly obtrusive medical procedures, adoption of sedentary lifestyle, and expanding geriatric populace are projected to boost the growth of this market in the coming years.

The Valvular Heart Disease treatment market is generating significant revenues on account of the expansion in the number of coronary artery disease. The developing geriatric populace is also boosting this market as they are more prone to valvular heart diseases and its adverse effects. This is further attributed to their developing age. People with regular drinking habits are also responsible for the rise in cases of heart diseases which ultimately promotes the growth of this market. The increasing use of minimally invasive surgeries will further augment the growth of this market in future.

Valvular Heart Disease Treatment Market Introduction

Pulmonic, aortic, mitral, and tricuspid are the four types of heart valves, which control the flow of blood across the heart chambers and their connecting arteries. Damage to any of the valves can lead to valvular diseases. Valvular diseases are treated by repairing or replacing the heart valves. Fatigue, swelling of feet or ankles, dizziness, abnormal sound, and irregular heartbeat are the symptoms of valvular heart disease. Valvular heart diseases can also be caused due to infection or other heart conditions. Congenital heart disease, heart failure, high blood pressure, and old age are the risk factors for valvular heart disease.

Valvular Heart Disease Treatment Market – Competition Landscape

The global valvular heart disease treatment market is highly consolidated with presence of few players holding major share of the market. Key players are engaged in the development of new products and technologies, extension of device indications, and product approvals. Leading players operating in the global valvular heart disease treatment market are Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Neovasc, Inc., Medtronic, Abbott, LifeNet Health, LivaNova plc, Micro Interventional Devices, Inc., Edwards Lifesciences Corporation, and CryoLife, Inc.

Boston Scientific Corporation:

Founded in 1960, the US based Boston Scientific Corporation is one of the key players operating in global valvular heart disease market, offering products under its cardiovascular business segment. It has a strong pipeline of innovative valvular heart disease treatment products. In April 2019, Boston Scientific Corporation received approval from the U.S. Food and Drug Administration for LOTUS Edge Aortic valve system for minimally invasive procedure.

Abbott:

Abbott is another key player operating in the global valvular heart disease market with vast product portfolio. Abbott has established its presence in the global market through acquisition of St. Jude Medical in 2017. In January 2019, Abbott acquired Cephea Valve Technologies, Inc. This acquisition enabled the company to strengthen its position in valvular heart disease market.

Medtronic:

Medtronic offers its valvular heart disease products under its Cardiac & Vascular Group (CVG). In 2018, around 38% of the company’s revenue was contributed by its CVG business segment. Medtronic has one of the industry leading portfolio of valvular heart disease treatment products.

Valvular Heart Disease Treatment Market Dynamics

High prevalence of valvular heart disease:

Rise in prevalence of coronary artery diseases, heart attack, and cardiovascular diseases is the major factor projected to drive the global valvular heart disease treatment market. Additionally, excessive consumption of alcohol and change in lifestyle are anticipated to propel the global market during the forecast period. Increase in adoption of minimally invasive techniques is another factor expected to augment the global valvular heart disease treatment market.

According to the World Health Organization, cardiovascular disease is one of the major causes of deaths across the world. CVDs such as heart attack and stroke account for 17.9 million deaths across the globe each year. Nearly 17.9 million deaths occurred in 2012 across the world due to cardiovascular diseases.

High cost of products to restrain the market expansion

Implantable devices such as heart valves, grafts and annuloplasty rings are the most recommended treatment options for valvular heart diseases. Limited number of suppliers and high precision and proprietary knowledge required for development and deployment of this devices incurs high cost. Also in case of using mechanical heart prosthetics, patients are on long term administration of blood thinners or anti-coagulant drugs which further makes the treatment expensive.

Valvular Heart Disease Treatment Market – Segmentation

The global valvular heart disease treatment market can be bifurcated on the basis of product type, treatment, application, and end-user

In terms of product type, the global valvular disease treatment market can be segmented into:

• Implantable Devices
• Valves
• Patches
• Grafts
• Others
• Medications

In terms of treatment, the global valvular heart disease treatment market can be classified into:

• Surgery
• Medication

In terms of application, the global valvular heart disease treatment market can be divided into:

• Congenital Heart Disease
• Valve Stenosis
• Valve Regurgitation
• Others

In terms of end-user, the global valvular heart disease treatment market can be classified into:

• Ambulatory Surgical Centers & Hospitals
• Specialty Clinics

The report on valvular heart disease treatment market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The valvular heart disease treatment market report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The valvular heart disease treatment market report also maps the qualitative impact of various market factors on valvular heart disease treatment market segments and geographies.

Regional analysis for walking standers market includes:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America dominated the global market in 2018. This is attributed to various factors such as presence of leading players, technological advancements, and rise in prevalence of cardiovascular diseases. According to the American Heart Association, 92.1 million people in the U.S. were suffering from cardiac diseases in 2018. The market in Europe is driven by rise in prevalence of heart diseases and increase in demand for minimally invasive procedures. According to the European Heart Network AISBL, around 3.9 million deaths occur due to cardiovascular diseases in Europe every year. The valvular heart disease treatment market in Asia Pacific is projected to grow at a rapid pace during the forecast period due to rise in prevalence of heart attack due to change in lifestyle.